Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
3.
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Eur J Nucl Med Mol Imaging
; 51(1): 295-303, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592084
4.
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Eur J Nucl Med Mol Imaging
; 50(13): 3970-3981, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563351
5.
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy.
Neuroendocrinology
; 113(3): 281-288, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36049462
6.
Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
J Nucl Cardiol
; 30(6): 2676-2691, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587328
7.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
8.
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer.
Eur J Nucl Med Mol Imaging
; 49(2): 763-776, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34383089
9.
PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
Clin Endocrinol (Oxf)
; 95(1): 13-28, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296100
10.
Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.
Eur J Nucl Med Mol Imaging
; 48(13): 4495-4507, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34136957
11.
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(2): 477-482, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696091
12.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
BJU Int
; 128(3): 331-342, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33682320
13.
Utility of 68 Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia.
Intern Med J
; 51(10): 1657-1664, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314504
14.
The Global Reading Room: Performing a Ventilation-Perfusion Study in a Patient With Recent COVID-19.
AJR Am J Roentgenol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691414
15.
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET.
Eur J Nucl Med Mol Imaging
; 50(1): 8-9, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962807
16.
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 44(3): 476-489, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27678267
17.
Correction to: Prospective intraindividual blinded comparison of [18F]PSMA1007 and [68 Ga]GaPSMA11 PET/CT imaging in patients with confirmed prostate cancer.
Eur J Nucl Med Mol Imaging
; 49(2): 789, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34729629
18.
Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(2): 655-656, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918575
19.
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort.
Eur Urol Focus
; 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195354
20.
Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging.
Intern Med J
; 48(1): 97-98, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29314520